Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02679729 · ClinicalTrials.gov registry record · Phase 1
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
A Phase 1 study of Cystic Fibrosis, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 2
- Study locations
NCT02679729 is a Phase 1 study of Cystic Fibrosis that has completed, run by AstraZeneca. The registered enrollment target is 63 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02679729, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1, first-in-human (FIH) single ascending dose study being conducted to better understand the safety, tolerability and pharmacokinetics of AZD5634 in healthy subjects
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD5634 for inhalation
- DRUG AZD5634 for infusion
Study Locations (2)
California
- Research Site - Glendale
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2016-02-11 |
| Est. Completion | 2016-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02679729
The ClinicalTrials.gov registry entry for NCT02679729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (65% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02679729 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT02679729 about?
NCT02679729 is a clinical study titled "To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration". This is a Phase 1, first-in-human (FIH) single ascending dose study being conducted to better understand the safety, tolerability and pharmacokinetics of AZD5634 in healthy subjects
What is the current status of trial NCT02679729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2016-02-11. Estimated completion is 2016-10-24.
What conditions does trial NCT02679729 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT02679729?
The interventions under investigation include: Placebo (OTHER), AZD5634 for inhalation (DRUG), AZD5634 for infusion (DRUG).
Who is sponsoring clinical trial NCT02679729?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02679729 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.